跳至主要内容
临床试验/EUCTR2008-002295-10-IT
EUCTR2008-002295-10-IT进行中(未招募)不适用

Role of immunosuppression with steroids in the outcome of fibrosis due to recurrent hepatitis C virus (HCV) infection after liver transplantation - Epaster 2

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI0 个研究点开始时间: 2008年6月12日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  •  Chronic hepatitis C carriers undergoing liver transplantation, also if concomitant hepatocellular carcinoma (HCC)  Age equal to or above 18 anni  Liver transplantation performed using cadaveric full-size graft  Negative serological status with regard to hepatitis B (HBV) infection with the exception of HBsAg / HBV-DNA negative but anti-HBs and/or anti-HBc positive recipients  Written approval of the informed consent according to ICH-GCP
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  •  Anti-HCV positive donor  HBsAg positive donor  AB0 incompatibile donor  Re-transplants  Alcoholic liver disease  HIV-positive recipients  Fulminant hepatic failure  Lack of compliance to the procedures scheduled in the protocol

研究者

发起方
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI

相似试验

Role of immunosuppression with steroids in the... | 临床试验